Trial Profile
A retrospective trial to evaluate cardiac safety of adjuvant trastuzumab in patients with HER2-positive early stage breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Feb 2016
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 01 Feb 2016 New trial record
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium